About
Platform gene-therapy company across ophthalmology, neurology and metabolic disease. Ophthalmology lead KRIYA-825 (AAV, suprachoroidal, complement inhibitor) initiated Phase 1/2 in 2025.
HQ: Palo Alto, CA & RTP, NC, USA
Funding
> $900M raised per company (2019–present)
Figures conflict ($430M–$1.2B across sources); company's own figure is the most defensible.